Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 152 No. 1920 (2022)

Assessment of SARS-CoV-2 tests costs and reimbursement tariffs readjustments during the COVID-19 pandemic

  • Giorgia Caruana
  • René Brouillet
  • Onya Opota
  • Gilbert Greub
DOI
https://doi.org/10.4414/SMW.2022.w30168
Cite this as:
Swiss Med Wkly. 2022;152:w30168
Published
13.05.2022

Summary

INTRODUCTION: While laboratories have been facing limited supplies of reagents for diagnostic tests throughout the course of the COVID-19 pandemic, national and international health plans, as well as billing costs, have been constantly adjusted in order to optimize the use of resources. We aimed to assess the impact of SARS-CoV-2 test costs and reimbursement tariff adjustments on diagnostic strategies in Switzerland to determine the advantages and disadvantages of different costs and resource saving plans.

MATERIALS AND METHODS: We specifically assessed the cost of diagnostic SARS-COV-2 RT-PCR using five different approaches: i) in-house platform, ii) cobas 6800® (Roche, Basel, Switzerland), iii) GeneXpert® SARS-CoV-2 test (Cepheid, Sunnyvale, CA, USA), iv) VIASURE SARS-CoV-2 (N1 + N2) Real-Time PCR Detection Kit for BD MAX™ (Becton Dickinson, Franklin Lake, NJ, USA), v) cobas® Liat® SARS-CoV-2 & Influenza A/B (Roche, Basel, Switzerland). We compared these costs to the evolution of the reimbursement tariffs.

RESULTS: The cost of a single RT-PCR test varied greatly (as did the volume of tests performed), ranging from as high as 180 CHF per test at the beginning of the pandemic (February to April 2020) to as low as 82 CHF per test at the end of 2020. Depending on the time period within the pandemic, higher costs did not necessarily mean greater benefits for the laboratories. The costs of molecular reagents for rapid tests were higher than of those for classic RT-PCR platforms, but the rapid tests had reduced turnaround times (TATs), thus improving patient care and enabling more efficient implementation of isolation measures, as well as reducing the burden of possible nosocomial infections. At the same time, there were periods when the production or distribution of these reagents was insufficient, and only the use of several different molecular platforms allowed us to sustain the high number of tests requested.

CONCLUSIONS: Cost-saving plans need to be thoroughly assessed and constantly adjusted according to the epidemiological situation, the clinical context and the national resources in order to always guarantee that the highest performing diagnostic solutions are available. Not all cost-saving strategies guarantee good analytical performance.

References

  1. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep. 2010 Apr;125(3 Suppl 3):16–26.
  2. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020 Mar;395(10228):931–4. https://doi.org/10.1016/S0140-6736(20)30567-5
  3. Bachman D. The economic impact of COVID-19 (novel coronavirus). https://www2.deloitte.com/us/en/insights/economy/covid-19/economic-impact-covid-19.html, 2020 2021).
  4. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks [CCLM]. Clin Chem Lab Med. 2020 Jun;58(7):1063–9. https://doi.org/10.1515/cclm-2020-0240
  5. Bundesgesetz über die Bekämpfung übertragbarer Krankheiten des Menschen. Loi fédérale sur la lutte contre les maladies transmissibles de l’homme. Legge federale sulla lotta contro le malattie trasmissibili dell'essere umano., in: D.B.d.S.E.L.A.f.d.l.C.s.L.A.f.d.C. Svizzera. (Ed.) 2012, p. 28.
  6. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung. Ordonnance du DFI sur les prestations dans l’assurance obligatoire des soins en cas de maladie. Ordinanza del DFI sulle prestazioni dell’assicurazione obbligatoria delle cure medico-sanitarie., in: D.E.D.d.I.L.D.f.d.l.i.I.D.f. dell’interno. (Ed.) 1995, p. 70.
  7. Greub G, Sahli R, Brouillet R, Jaton K. Ten years of R&D and full automation in molecular diagnosis. Future Microbiol. 2016;11(3):403–25. https://doi.org/10.2217/fmb.15.152
  8. Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples. Pathog Dis. 2020 Nov;78(8):ftaa061. https://doi.org/10.1093/femspd/ftaa061
  9. Marquis B, Opota O, Jaton K, Greub G. Impact of different SARS-CoV-2 assays on laboratory turnaround time. J Med Microbiol. 2021 May;70(5). https://doi.org/10.1099/jmm.0.001280
  10. Pillonel T, Scherz V, Jaton K, Greub G, Bertelli C. Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR, Euro Surveill 25(21) (2020).
  11. Moraz M, Jacot D, Papadimitriou-Olivgeris M, Senn L, Greub G, Jaton K, et al. Universal admission screening strategy for COVID-19 highlighted the clinical importance of reporting SARS-CoV-2 viral loads. New Microbes New Infect. 2020 Nov;38:100820. https://doi.org/10.1016/j.nmni.2020.100820
  12. Reddy SR, Ross-Degnan D, Zaslavsky AM, Soumerai SB, Wharam JF. Impact of a high-deductible health plan on outpatient visits and associated diagnostic tests. Med Care. 2014 Jan;52(1):86–92. https://doi.org/10.1097/MLR.0000000000000008
  13. Wacharapluesadee S, Kaewpom T, Ampoot W, Ghai S, Khamhang W, Worachotsueptrakun K, et al. Evaluating the efficiency of specimen pooling for PCR-based detection of COVID-19. J Med Virol. 2020 Oct;92(10):2193–9. https://doi.org/10.1002/jmv.26005
  14. Ben-Ami R, Klochendler A, Seidel M, Sido T, Gurel-Gurevich O, Yassour M, et al.; Hebrew University-Hadassah COVID-19 Diagnosis Team. Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection. Clin Microbiol Infect. 2020 Sep;26(9):1248–53. https://doi.org/10.1016/j.cmi.2020.06.009
  15. Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al. Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: the INCREASE Study. Microorganisms. 2021 Apr;9(4):798. https://doi.org/10.3390/microorganisms9040798
  16. Caruana G, Lebrun LL, Aebischer O, Opota O, Urbano L, de Rham M, et al. The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients. New Microbes New Infect. 2021 Jul;42:100899. https://doi.org/10.1016/j.nmni.2021.100899
  17. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clin Microbiol Infect. 2021;27(4):636.e1–4. https://doi.org/10.1016/j.cmi.2020.12.022
  18. Adrian Egli RL. Katia Jaton, Gilbert Greub, Recommendation of the Swiss Society of Microbiology for usage of SARS-CoV-2 specific antigen tests, Pipette - Swiss. Lab Med. 2020;6:18–20.
  19. FOPH. Coronavirus : Tests. https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/testen.html, (accessed January 25.2021).
  20. Ladoy A, Opota O, Carron PN, Guessous I, Vuilleumier S, Joost S, et al. Size and duration of COVID-19 clusters go along with a high SARS-CoV-2 viral load : a spatio-temporal investigation in Vaud state, Switzerland, (2021) 2021.02.16.21251641.

Most read articles by the same author(s)